Literature DB >> 25931465

Protective Role of Peroxisome Proliferator-Activated Receptor-γ in the Development of Intracranial Aneurysm Rupture.

Kenji Shimada1, Hajime Furukawa1, Kosuke Wada1, Masaaki Korai1, Yuan Wei1, Yoshiteru Tada1, Atsushi Kuwabara1, Fumiaki Shikata1, Keiko T Kitazato1, Shinji Nagahiro1, Michael T Lawton1, Tomoki Hashimoto2.   

Abstract

BACKGROUND AND
PURPOSE: Inflammation is emerging as a key component of the pathophysiology of intracranial aneurysms. Peroxisome proliferator-activated receptor-γ (PPARγ) is a nuclear hormone receptor of which activation modulates various aspects of inflammation.
METHODS: Using a mouse model of intracranial aneurysm, we examined the potential roles of PPARγ in the development of rupture of intracranial aneurysm.
RESULTS: A PPARγ agonist, pioglitazone, significantly reduced the incidence of ruptured aneurysms and the rupture rate without affecting the total incidence aneurysm (unruptured aneurysms and ruptured aneurysms). PPARγ antagonist (GW9662) abolished the protective effect of pioglitazone. The protective effect of pioglitazone was absent in mice lacking macrophage PPARγ. Pioglitazone treatment reduced the mRNA levels of inflammatory cytokines (monocyte chemoattractant factor-1, interleukin-1, and interleukin-6) that are primarily produced by macrophages in the cerebral arteries. Pioglitazone treatment reduced the infiltration of M1 macrophage into the cerebral arteries and the macrophage M1/M2 ratio. Depletion of macrophages significantly reduced the rupture rate.
CONCLUSIONS: Our data showed that the activation of macrophage PPARγ protects against the development of aneurysmal rupture. PPARγ in inflammatory cells may be a potential therapeutic target for the prevention of aneurysmal rupture.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  inflammation; intracranial aneurysm; subarachnoid hemorrhage

Mesh:

Substances:

Year:  2015        PMID: 25931465      PMCID: PMC4447500          DOI: 10.1161/STROKEAHA.114.007722

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  33 in total

1.  Activation of signal transducer and activator of transcription-3 by a peroxisome proliferator-activated receptor gamma agonist contributes to neuroprotection in the peri-infarct region after ischemia in oophorectomized rats.

Authors:  Tomoya Kinouchi; Keiko T Kitazato; Kenji Shimada; Kenji Yagi; Yoshiteru Tada; Nobuhisa Matsushita; Manabu Sumiyoshi; Junichiro Satomi; Teruyoshi Kageji; Shinji Nagahiro
Journal:  Stroke       Date:  2011-11-10       Impact factor: 7.914

2.  Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture.

Authors:  Michael Tymianski
Journal:  Stroke       Date:  2011-10-06       Impact factor: 7.914

3.  Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice.

Authors:  Aijuan Qu; Yatrik M Shah; Soumen K Manna; Frank J Gonzalez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-20       Impact factor: 8.311

Review 4.  Protecting against vascular disease in brain.

Authors:  Frank M Faraci
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

5.  Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture.

Authors:  David M Hasan; Kelly B Mahaney; Robert D Brown; Irene Meissner; David G Piepgras; John Huston; Ana W Capuano; James C Torner
Journal:  Stroke       Date:  2011-10-06       Impact factor: 7.914

6.  Regression of intracranial aneurysms by simultaneous inhibition of nuclear factor-κB and Ets with chimeric decoy oligodeoxynucleotide treatment.

Authors:  Tomohiro Aoki; Hiroharu Kataoka; Masaki Nishimura; Ryota Ishibashi; Ryuichi Morishita; Susumu Miyamoto
Journal:  Neurosurgery       Date:  2012-06       Impact factor: 4.654

Review 7.  Effects of PPARγ agonists against vascular and renal dysfunction.

Authors:  Akira Sugawara; Akira Uruno; Ken Matsuda; Takako Saito-Ito; Tadao Funato; Akiko Saito-Hakoda; Masataka Kudo; Sadayoshi Ito
Journal:  Curr Mol Pharmacol       Date:  2012-06       Impact factor: 3.339

8.  Peroxisome proliferator-activated receptor-γ agonists prevent in vivo remodeling of human artery induced by alloreactive T cells.

Authors:  Zuzana Tobiasova; Lufeng Zhang; Tai Yi; Linfeng Qin; Thomas D Manes; Sanjay Kulkarni; Marc I Lorber; Frederick C Rodriguez; Je-Min Choi; George Tellides; Jordan S Pober; Ivana Kawikova; Alfred L M Bothwell
Journal:  Circulation       Date:  2011-06-20       Impact factor: 29.690

9.  Elastase-induced intracranial aneurysms in hypertensive mice.

Authors:  Yoshitsugu Nuki; Tsung-Ling Tsou; Chie Kurihara; Miyuki Kanematsu; Yasuhisa Kanematsu; Tomoki Hashimoto
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

10.  Rosiglitazone reduces the development and rupture of experimental aortic aneurysms.

Authors:  Alun Jones; Rajdeep Deb; Evelyn Torsney; Franklyn Howe; Mathew Dunkley; Yanosha Gnaneswaran; David Gaze; Hosaam Nasr; Ian M Loftus; Mathew M Thompson; Gillian W Cockerill
Journal:  Circulation       Date:  2009-06-08       Impact factor: 29.690

View more
  34 in total

Review 1.  Flow-induced, inflammation-mediated arterial wall remodeling in the formation and progression of intracranial aneurysms.

Authors:  Juhana Frösen; Juan Cebral; Anne M Robertson; Tomohiro Aoki
Journal:  Neurosurg Focus       Date:  2019-07-01       Impact factor: 4.047

2.  M1 macrophages are required for murine cerebral aneurysm formation.

Authors:  Kamil W Nowicki; Koji Hosaka; Frank J Walch; Edward W Scott; Brian L Hoh
Journal:  J Neurointerv Surg       Date:  2017-02-14       Impact factor: 5.836

3.  [Value of 640-slice 3D CT angiography plus 3D printing for improving surgeries for intracranial aneurysms].

Authors:  Lu-Qiu Zhou; Ming-Wu Lou; Guo-Chang Chen; Zhi-Song Jiu; Yun-Xia Shen; Lin Lu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-09-20

4.  Noninvasive Vagus Nerve Stimulation Prevents Ruptures and Improves Outcomes in a Model of Intracranial Aneurysm in Mice.

Authors:  Tomoaki Suzuki; Tsubasa Takizawa; Yoshinobu Kamio; Tao Qin; Tomoki Hashimoto; Yukihiko Fujii; Yuichi Murayama; Aman B Patel; Cenk Ayata
Journal:  Stroke       Date:  2019-05       Impact factor: 7.914

5.  Recombinant Netrin-1 binding UNC5B receptor attenuates neuroinflammation and brain injury via PPARγ/NFκB signaling pathway after subarachnoid hemorrhage in rats.

Authors:  Zongyi Xie; Lei Huang; Budbazar Enkhjargal; Cesar Reis; Weifeng Wan; Jiping Tang; Yuan Cheng; John H Zhang
Journal:  Brain Behav Immun       Date:  2017-11-21       Impact factor: 7.217

6.  Alternative activation-skewed microglia/macrophages promote hematoma resolution in experimental intracerebral hemorrhage.

Authors:  Che-Feng Chang; Jieru Wan; Qiang Li; Stephen C Renfroe; Nicola M Heller; Jian Wang
Journal:  Neurobiol Dis       Date:  2017-03-30       Impact factor: 5.996

7.  Interleukin-6 Promotes Murine Estrogen Deficiency-Associated Cerebral Aneurysm Rupture.

Authors:  Daisuke Wajima; Siham Hourani; William Dodd; Devan Patel; Chad Jones; Kartik Motwani; Hanain Z Fazal; Koji Hosaka; Brian L Hoh
Journal:  Neurosurgery       Date:  2020-04-01       Impact factor: 4.654

8.  Protective Effect of Mesenchymal Stem Cells Against the Development of Intracranial Aneurysm Rupture in Mice.

Authors:  Atsushi Kuwabara; Jia Liu; Yoshinobu Kamio; Airan Liu; Michael T Lawton; Jae-Woo Lee; Tomoki Hashimoto
Journal:  Neurosurgery       Date:  2017-12-01       Impact factor: 4.654

9.  TLR4 (Toll-Like Receptor 4) Mediates the Development of Intracranial Aneurysm Rupture.

Authors:  Kazuha Mitsui; Taichi Ikedo; Yoshinobu Kamio; Hajime Furukawa; Michael T Lawton; Tomoki Hashimoto
Journal:  Hypertension       Date:  2019-12-23       Impact factor: 10.190

10.  Mast Cell Promotes the Development of Intracranial Aneurysm Rupture.

Authors:  Hajime Furukawa; Kosuke Wada; Yoshiteru Tada; Atsushi Kuwabara; Hiroki Sato; Jinglu Ai; Michael T Lawton; Tomoki Hashimoto
Journal:  Stroke       Date:  2020-10-06       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.